Kenneth J. Zuerblis

Mr. Zuerblis was formerly Executive Vice President and Chief Financial Officer of Savient Pharmaceuticals, Inc., a position he held until May 2012. Prior to joining Savient, Mr. Zuerblis served as Chief Financial Officer and Senior Vice President at ImClone Systems from 2008 through 2009. In that role, he was responsible for the strategic planning and leadership of finance and related operations and helped lead all aspects of the sale of the company to Eli Lilly and Company. From 1994 through 2005, Mr. Zuerblis served as Chief Financial Officer of Enzon Pharmaceuticals Inc. and held the position of Corporate Controller from 1991 through 1994. Enzon developed the first three FDA-approved products using PEGylation technology. Most notably during Mr. Zuerblis’ 14-year tenure, Enzon transformed from an early-stage biotechnology company into a fully integrated biopharmaceutical company with five marketed products.

Mr. Zuerblis earned his Bachelor of Science in Accounting from Seton Hall University and is a certified public accountant in the State of New Jersey.

Mr. Zuerblis also serves on the Board of Directors of Resverlogix Corp. and Stemline Therapeutics.